



ASX / MEDIA RELEASE

ResApp Enrols First Patient in SMARTCOUGH-C-2 Study

Brisbane, Australia, 8 January 2018 -- ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has enrolled the first patient in its SMARTCOUGH-C-2 study in the United States. The study is a prospective, multi-site, double blind study to evaluate the efficacy of the ResAppDx smartphone application in the diagnosis of childhood respiratory diseases from cough sounds.

The SMARTCOUGH-C-2 study plans to enrol up to 1,667 patients aged 29 days to 12 years of age who present to one of the three participating sites in the United States with signs or symptoms of respiratory disease. The study's co-primary endpoints are positive and negative percent agreement with clinical diagnosis for pneumonia, lower respiratory tract disease, viral lower respiratory tract infection, bronchiolitis, asthma/reactive airways disease, upper respiratory tract disease and croup. The clinical diagnosis will be made by an independent, centralised clinical adjudication committee using all available clinical data, including radiology and microbiology.

"We are excited to begin the study and take this important next step towards the commercialisation of ResAppDx in the United States," said Tony Keating, CEO and Managing Director of ResApp. "The refined study protocol, developed in close collaboration with the principal investigators at the recruiting sites, includes major improvements over our previous study in the United States and we look forward to obtaining results which are a true representation of ResAppDx's performance in mid 2018."

More information on the study is available at www.clinicaltrials.gov (NCT03392363).

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use cough sounds to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has adult and paediatric clinical studies underway at leading US and Australian hospitals with results demonstrating accurate diagnosis of pneumonia, asthma/reactive airways disease, bronchiolitis, croup, chronic obstructive pulmonary disease and upper respiratory tract infections. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world.

In the United States, ResAppDx is an investigational device and is not available for sale.

ResApp Health Limited ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 22, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 **E** info@resapphealth.com.au **W** www.resapphealth.com.au



For more information on ResApp, visit www.resapphealth.com.au

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

ResApp Health Limited ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 22, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 **E** info@resapphealth.com.au **W** www.resapphealth.com.au